3M Company (MMM)

Total return at 5 years: 7.4%/year = 5.3% appreciation + 2.1% dividend. The target price ($211) is ex-dividend; the $19 in dividends collected over 5 years are added separately.

By both methods, the value today (DCF $272 · Multiples $186) exceeds the market price ($163).

Today — fairly valued: at $163 trades ~12.5% below its value discounted to today (~$186); the discount is positive but does not reach the margin of safety we require (≥38%).

At 5 years — En valor: the target price ($211) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.

The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$118.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($163) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The market discounts less growth (-4.3%/year) than we project (6.0%/year) → if the base case holds, there is margin: perception is more pessimistic than the estimated reality.

That growth implies ~$4.2 bn of owner earnings in year 5 (vs ~$7 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). The flow is returned almost in full (dividend + buyback) or redeployed into the operation, so that EV stays roughly flat and multiples compress because the metric grows, not because of cash accumulation. The valuation is done on EV/EBIT — EBIT ajustado (ex-especiales). In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

Year 0 is the TTM ended 30-Jun-2026 (revenue US$25.18bn GAAP). Year-0 EBIT is taken on an adjusted basis (US$5.869bn, a 23.6% margin, from the Q2'26 release itself) because GAAP TTM EBIT (US$4.624bn) is depressed by special items that do not recur at the same pace going forward: PFAS and earplug litigation, the exit from PFAS manufacturing, divestiture losses and transformation costs. The year-1 starting point is anchored to the current guidance in the release of 21-Jul-2026 with both of its anchors: revenue (total adjusted growth above 4.5%, organic above 3.5%) and adjusted earnings per share (US$8.80-8.95, midpoint ~US$8.88), which together with the guided adjusted operating margin (expansion of 70-80 basis points) and the guided adjusted effective tax rate (~20%) set the year-1 net margin at around 17.3%. Years 2 to 5 smoothly decelerate revenue growth from 4.5% to 3.5% (the durable growth band of a mature industrial with exposure to semiconductors/data centers and automotive/aerospace) while the margin keeps expanding gradually, consistent with the company's transformation program. Buybacks are very large relative to the dividend (US$4.02bn TTM against US$1.59bn TTM): they are modeled with an explicit `sharesPath` and `accumulateCash:false`, with `fcfLtm`/`buybackLtm` loaded from real cash flow levels so the cascade computes real retention and does not count the surplus twice. Financial debt (US$12.55bn) and cash (US$2.96bn) enter the bridge as befits an EV-level metric (EV/EBIT, not P/E): the exit multiple no longer absorbs the leverage, the bridge does. The litigation liabilities (the PWS settlement of ~US$10.5-12.5bn between 2024 and 2036, the earplug settlement of ~US$6bn between 2023 and 2029) are already recognized as liabilities on the balance sheet and their financing cost (imputed interest) already reduces reported net income; they are not separated as additional debt beyond financial debt because there is no way to cleanly isolate their portion within the balance sheet's «other liabilities» line without inventing a number — they are declared as the dominant risk in the bear case and in the health note.

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (the metric grows while EV stays roughly flat). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $211 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $163, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $211 in 5 years plus $19 of dividends collected (the dividend adds to the return, not to the price) and a required return of 4.5% annually, the maximum to pay today is $186. Against the current market price ($163), the margin of safety is 12.5% (trades below the maximum → there is margin) and the total return at that price would be 7.4% annually.

• Implied entry multiple. The adjusted EV/EBIT multiple at today's price (16×) is close to the ceiling of the industrial archetype band (12-18×).
• Base case exit multiple. 13× terminal EV/EBIT, in the lower third of the band given the eroding moat and litigation risk.
• 5-year total return (base case). +7% annually at the market price, including the dividend yield (~1.7% today, growing).
• Margin of safety. It trades close to intrinsic value, far from the required margin of safety.

Each margin over sales, year by year: historical (solid line) → projection (dotted).

• ✓ ROIC exceeds the cost of capital (~10%)
• ✓ CFROIC backs up the ROIC (111%, cash vs. accruals)
• ✓ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• Cash generation. TTM operating cash flow is inflated by a one-time 2025 litigation payment rolling out of the trailing window; the guided adjusted cash flow conversion (>100%) is the cleaner reference going forward.
• ROIC vs the 10% bar. ROIC on real invested capital comes out well above 10%, but inflated by an invested capital base contracted by litigation payments — the caveat is declared in the profitability note.
• Reinvestment runway. Capex below depreciation ($0.91bn versus $1.39bn TTM), a sign of a business without intensive growth-investment needs rather than an attractive reinvestment runway.
• Accounting distortions. Large, recurring special items (litigation, the change in value of Solventum, transformation costs) require normalizing GAAP EBIT and net income to read the business's real economics.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

3M does not disclose volumes or physical units at the segment level in its annual report; the best available level is reported segment revenue. The correct reading is not a consolidated average: Safety and Industrial is today the growth engine, Transportation and Electronics is recovering after the PFAS manufacturing exit, and Consumer keeps contracting — a business running at three different speeds, not a monolith.

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (30-jun-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• 2026 guidance. Total adjusted growth >4.5% (organic >3.5%), raised from initial guidance.
• Leading segment. Safety and Industrial grew 8.2% organic in the second quarter of 2026, the driver of the reacceleration.
• Lagging segment. Consumer keeps contracting organically (-2.1% in the second quarter of 2026).
• Durable 5-year growth. Projected at 3.5% annually by year 5, a reasonable band for a mature industrial without over-extrapolating the recent reacceleration.

• Segment diversification. Three segments with different dynamics (Safety and Industrial growing, Transportation and Electronics recovering, Consumer contracting) reduce dependence on a single end market.
• Broad geographic exposure. 56% of revenue outside the United States, with relevant currency and tariff exposure.
• Brand portfolio. Century-old consumer brands (Scotch, Post-it, Command) with proven channel loyalty.
• Recent growth track record. Three years of negative or flat organic growth (2023-2025) before the 2026 reacceleration.
• Dependence on product renewal. Future growth depends on market acceptance of new products in a pipeline the company does not quantify at the unit level.

Not all debt is equal: only the structural needs refinancing; the rest is operational (self-liquidating).

Structural debt is what is exposed to the contraction phase of the cycle; operational debt (leases, matched funding) self-liquidates with the business.

• !Leverage (net debt / EBITDA)Net debt / EBITDA 1.3x
• !Interest coverage (EBIT / interest)6.3x
• –Liquidity (current ratio)no data
• ✓Cash quality (CFROIC vs ROIC)CFROIC backs 111% of ROIC
• ✓Value creation (ROIC − 10% bar)+28pp
• ✓Malinvestment test (capex vs incremental ROIC)Capex/D&A 0.7x — no over-investment
• !Float / working capitalConsumes cash $0.1 bn (positive WC)
• ✓Dilution (SBC % of revenue + shares)SBC 0.9% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Credit rating. Stable investment grade (A3 Moody's, BBB+ S&P, A- Fitch).
• Net debt. $9.60bn of net debt ($12.55bn of financial debt against $2.96bn of cash) on TTM adjusted EBIT of $5.87bn.
• Multi-year litigation liabilities. Payment commitments through 2036 (PFAS) and 2029 (combat earplugs) that consume cash predictably but materially every year.
• Short-term liquidity. Cash of $2.96bn plus $0.375bn in marketable securities comfortably covers short-term debt ($1.65bn).

Who owns the shares — the alignment and whether there is a controlling shareholder.

• CEO track record. Brown joined in 2024 with a specific restructuring mandate; he executed the PFAS exit and raised guidance twice, but still has a short track record at 3M.
• Capital allocation. Buybacks dominant ($4.02bn TTM) over the dividend ($1.59bn); capex below depreciation, consistent with a mature business.
• Litigation transparency. The company details amounts, timelines, and methodology of the PFAS and combat earplug settlements in every filing, with explicit non-GAAP reconciliations.
• Skin in the game. The proxy does not disaggregate individual executive share ownership with a specific percentage in the available material; the gap is declared.

• Recovery from over-punishment in its prior phase: the stock was coming off years of negative organic growth and massive litigation that dominated market sentiment, and only in 2026 did the revenue reacceleration and the guidance increases start being recognized in the price.
• Persistent litigation noise: although the PFAS and combat earplug settlements are already provisioned, uncertainty over additional litigation (AFFF, new regulatory claims) still weighs on the multiple the market is willing to pay.
• Post-spin-off complexity: the story of two simultaneous transitions (the Solventum and PFAS exits) made year-over-year comparability harder, which may have delayed the re-rating until the continuing-operations series became clearer.

The price already reflects much of this story, so the remaining margin of safety is smaller than what buying before the reacceleration would have offered — It trades close to intrinsic value, far from the required margin of safety.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at -2%/year (-8% total): the margin of safety protects the downside. The bull (+14%/year, +96% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• PFAS litigation. PWS settlement of $10.5-12.5bn between 2024 and 2036, with additional litigation (AFFF) still unbounded.
• Combat earplugs. $6bn settlement between 2023 and 2029, with opt-out claimants as a residual risk.
• Currency and tariff risk. 56% of revenue outside the U.S.; tariffs and geopolitical tensions can raise input costs and disrupt supply chains.
• Global ERP system execution. The phased rollout introduces operational disruption risk during the transition.
• Price already reflects the recovery. The price already recognizes the recovery, reducing the margin for error available if the revenue reacceleration does not hold.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  Fails the quality gate: narrow moat, eroding.

• Peter Lynch Growth at a reasonable price (GARP)

  A cyclical growing 6% at a multiple/growth of 2.6 → expensive for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 6% (EBIT/EV) + ROIC 38% → brushes the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts -4% vs our 6%: perception is more pessimistic than reality, with an identified source of the discount.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor -4%/yr, bull-scenario ceiling +13%/yr over 5y: reasonable asymmetry, without an ample cushion.

• Pat Dorsey Moat strength (Five Rules)

  A narrow moat, eroding; sources: switching costs, efficient scale, intangibles, cost advantage → fails the Five Rules.

• Aswath Damodaran Expectations implied by the price

  Justifying the price requires discounting -4%, within what we project (6%) — the story squares with the numbers.